iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://www.ncbi.nlm.nih.gov/pubmed/16027765
15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005;7(3):106-13.
doi: 10.4088/pcc.v07n0305.

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

Affiliations

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

Maurizio Fava et al. Prim Care Companion J Clin Psychiatry. 2005.

Abstract

Background: Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, a twice-daily sustained-release formulation followed in 1996, and, in August 2003, a once-daily extended-release formulation was introduced. On the 15th anniversary of its introduction, we undertook a review of the background/history, mechanism of action, formulations, and clinical profile of bupropion.

Data sources: Major efficacy trials and other reports were obtained and reviewed from MEDLINE searches, review of abstracts from professional meetings, and the bupropion SR manufacturer's databases. Searches of English-language articles were conducted from June 2003 through August 2004. No time limit was specified in the searches, which were conducted using the search terms bupropion, bupropion SR, and bupropion XL.

Data synthesis: Bupropion inhibits the re-uptake of norepinephrine and dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. Bupropion is an effective antidepressant with efficacy comparable to selective serotonin reuptake inhibitors and other antidepressants. It is well tolerated in short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, and dizziness are the most common adverse events. Seizure and allergic reactions are medically important adverse events associated with bupropion and are reported rarely. Among all the newer antidepressants in the United States, bupropion appears to have among the lowest incidence of sexual dysfunction, weight gain, and somnolence. Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents.

Conclusion: Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Steady-State Plasma Level Concentrations for Bupropion 300 mg/day for IR, SR, and XL Formulationsa
Figure 2.
Figure 2.
Bedtime Steady-State Plasma Levels for Bupropion XL Compared to Bupropion SRa
Figure 3.
Figure 3.
Prevalence of Somnolence in Bupropion SR Clinical Trials

Similar articles

Cited by

References

    1. Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry. 1983 44(sec 2). 67–73. - PubMed
    1. Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000
    1. Wellbutrin (bupropion) tablets, Wellbutrin SR (bupropion), and Wellbutrin XL (bupropion). Physician's Desk Reference. Montvale, NJ: Thomson PDR. 2005 1655–1659. 1659,–1663. 1663–1668.
    1. Dunner DL, Zisook S, and Billow AA. et al. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry. 1998 59:366–373. - PubMed
    1. Johnston JA, Fiedler-Kelly J, and Glover ED. et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation. Nicotine Tob Res. 2001 3:131–140. - PubMed